Perspective Therapeutics

Yahoo Finance • 12 days ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body,... Full story

Yahoo Finance • 28 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on tra... Full story

Yahoo Finance • last month

Perspective Therapeutics Q4 2025 Earnings Preview

* Perspective Therapeutics (CATX [https://seekingalpha.com/symbol/CATX]) is scheduled to announce Q4 earnings results on Monday, March 16th, after market close. * The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/CA... Full story

Yahoo Finance • 2 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today... Full story

Yahoo Finance • 4 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics, Inc. SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for... Full story

Yahoo Finance • 4 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, t... Full story

Yahoo Finance • 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight... Full story

Yahoo Finance • 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body,... Full story

Yahoo Finance • 7 months ago

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics, Inc. First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.... Full story

Yahoo Finance • 7 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today annou... Full story

Yahoo Finance • 8 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announ... Full story

Yahoo Finance • 8 months ago

PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) Surpasses Q2 2025 Revenue Estimates with Narrower Loss

PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX [https://www.chartmill.com/stock/quote/CATX/profile]) reported its second-quarter 2025 financial results, delivering revenue that significantly surpassed analyst expectations while posting a narr... Full story

Yahoo Finance • 8 months ago

Perspective Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $0.29M beats by $0.12M

* Perspective Therapeutics press release [https://seekingalpha.com/pr/20199058-perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results] (NYSE:CATX [https://seekingalpha.com/symbol/CATX]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 8 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (OTCPK:TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Stratasys Ltd. (SSYS [https://seekingalpha.com/symbol/SSYS]) * Organigram Global (OGI [... Full story

Yahoo Finance • 9 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announc... Full story

Yahoo Finance • 10 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (Perspective or the Company) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two pr... Full story

Yahoo Finance • 11 months ago

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Perspective Therapeutics, Inc. (NYSE:CATX) was one of the stocks that was covered in that article. Wall Street analysts believe CATX has a 460% upside pot... Full story

Yahoo Finance • 3 years ago

Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American... Full story

Yahoo Finance • 3 years ago

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease. SEA... Full story

Yahoo Finance • 3 years ago

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 21... Full story